Captrust Financial Advisors Sells 2,012 Shares of ARK Genomic Revolution ETF (BATS:ARKG)

Captrust Financial Advisors decreased its holdings in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 10.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,953 shares of the company’s stock after selling 2,012 shares during the quarter. Captrust Financial Advisors’ holdings in ARK Genomic Revolution ETF were worth $399,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Barclays PLC increased its position in ARK Genomic Revolution ETF by 252.7% during the 3rd quarter. Barclays PLC now owns 285,108 shares of the company’s stock worth $7,299,000 after purchasing an additional 204,283 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of ARK Genomic Revolution ETF by 45,400.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 252,530 shares of the company’s stock worth $5,946,000 after buying an additional 251,975 shares during the last quarter. Prudential PLC increased its holdings in shares of ARK Genomic Revolution ETF by 10.5% during the fourth quarter. Prudential PLC now owns 160,370 shares of the company’s stock worth $3,776,000 after buying an additional 15,200 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in shares of ARK Genomic Revolution ETF in the 4th quarter valued at $2,424,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of ARK Genomic Revolution ETF during the 4th quarter valued at $2,027,000.

ARK Genomic Revolution ETF Stock Performance

Shares of ARKG stock opened at $21.46 on Tuesday. ARK Genomic Revolution ETF has a twelve month low of $17.51 and a twelve month high of $31.16. The stock’s fifty day simple moving average is $21.45 and its 200 day simple moving average is $23.97.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.